Is Buying Antares Pharma Inc (NASDAQ:ATRS), Having Higher Short Interest a Winning Strategy?

November 10, 2018 - By Hazel Jackson

Investors sentiment increased to 1.41 in 2018 Q2. Its up 0.61, from 0.8 in 2018Q1. It is positive, as 9 investors sold Antares Pharma, Inc. shares while 20 reduced holdings. 15 funds opened positions while 26 raised stakes. 59.50 million shares or 6.29% more from 55.98 million shares in 2018Q1 were reported.
Falcon Point Cap Limited Liability Company owns 0.11% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 222,501 shares. 146,034 are owned by Raymond James Serv Advisors. Panagora Asset Management Inc, a Massachusetts-based fund reported 1.30 million shares. Morgan Stanley, a New York-based fund reported 648,649 shares. Metropolitan Life Insurance Company has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). State Street Corp reported 2.50 million shares or 0% of all its holdings. American reported 94,049 shares. M&T Savings Bank reported 0% in Antares Pharma, Inc. (NASDAQ:ATRS). 1.82M were reported by Jw Asset Limited Liability Company. Brown Advisory Secs Ltd Liability Corp holds 275,000 shares or 0.12% of its portfolio. 4,913 are held by Bnp Paribas Arbitrage Sa. Bankshares Of America Corp De holds 43,381 shares. Ameritas Invest Prtn Inc has 12,612 shares for 0% of their portfolio. Bancorporation Of Montreal Can reported 1,022 shares. Moreover, Zuckerman Investment Limited Liability Company has 0.06% invested in Antares Pharma, Inc. (NASDAQ:ATRS).

Since May 14, 2018, it had 0 buys, and 10 insider sales for $3.18 million activity. Shares for $161,250 were sold by APPLE ROBERT F on Tuesday, August 21.

The stock of Antares Pharma Inc (NASDAQ:ATRS) registered an increase of 9.57% in short interest. ATRS’s total short interest was 6.33M shares in November as published by FINRA. Its up 9.57% from 5.77 million shares, reported previously. With 1.86M shares average volume, it will take short sellers 3 days to cover their ATRS’s short positions. The short interest to Antares Pharma Inc’s float is 4.77%.

The stock increased 0.83% or $0.03 during the last trading session, reaching $3.64. About 1.24 million shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 10.07% since November 10, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $573.07 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

More notable recent Antares Pharma, Inc. (NASDAQ:ATRS) news were published by: Nasdaq.com which released: “Antares Pharma to Report Third Quarter 2018 Financial and Operating Results” on October 30, 2018, also Globenewswire.com with their article: “Antares Pharma Reports Third Quarter 2018 Operating and Financial Results” published on November 06, 2018, Nasdaq.com published: “Antares Pharma to Present at the Jefferies 2018 Global Healthcare Conference” on November 08, 2018. More interesting news about Antares Pharma, Inc. (NASDAQ:ATRS) were released by: Businesswire.com and their article: “Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to Class Action” published on November 09, 2018 as well as Nasdaq.com‘s news article titled: “Detailed Research: Economic Perspectives on Kohl’s, Activision Blizzard, Amerco, Cree, Antares Pharma, and Uranium …” with publication date: October 24, 2018.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>